Observational studyJournal of neurology2026
Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.
Massimo Filippi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.